Clinical Trials Logo

Cervical Intraepithelial Neoplasia clinical trials

View clinical trials related to Cervical Intraepithelial Neoplasia.

Filter by:

NCT ID: NCT02605941 Recruiting - Cervical Cancer Clinical Trials

DNA Methylation Biomarkers for Cervical Cancer Screening

Start date: February 2014
Phase: N/A
Study type: Observational

The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.

NCT ID: NCT02576262 Recruiting - Cervical Cancer Clinical Trials

HPV Integration Testing for Human Papillomavirus-Positive Women

Start date: September 2015
Phase: N/A
Study type: Observational

Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. the investigators evaluated the potential role of HPV Integration detection in cervical exfoliated cells in HPV-positive women from a clinic-based population.

NCT ID: NCT02576158 Recruiting - Cervical Cancer Clinical Trials

HPV Integration Testing for Cervical Cancer Screening

Start date: April 2015
Phase: N/A
Study type: Observational

The primary objective is to determine the sensitivity and specificity of the HPV Integration-based cervical screening for detection of high-grade cervical intraepithelial neoplasia (CIN), using colposcopic inspection as the reference method. Lesions will be confirmed as malignant or CIN by colposcopic inspection and histopathologic examination.

NCT ID: NCT02554344 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)

Start date: March 2016
Phase: Phase 0
Study type: Interventional

The purpose of this study is to determine the safety, feasibility, and regression rate of using curcumin in patients with Cervical Intraepithelial neoplasias (CIN3). The secondary objectives of this study is to evaluate patients with CIN3 for the presence of high-risk Human papillomavirus (HPV) and to perform an inflammatory panel on dysplasia biopsies from patients with CIN3 to determine which factors play a role in persistence of CIN3.

NCT ID: NCT02406352 Recruiting - Clinical trials for High Grade Cervical Intraepithelial Neoplasia

Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia

MDCwProbe
Start date: March 2015
Phase: N/A
Study type: Interventional

Although cervical cancer is a preventable cancer, every year more than one-quarter of a million women die worldwide from this disease. Internationally and nationally, cervical cancer is a disease that affects predominantly women who are poor and who live in resource poor settings. With the device the investigators are developing, known as the Multispectral Digital Colposcope with probe, our goal is to make detection of precancerous cervical lesions easier for the patient and for her provider. For the patient, our goal is to reduce the number of clinical visits needed to obtain a diagnosis and treatment and consequently to reduce the resulting fear and anxiety which usually accompanies an abnormal Pap smear. For the provider and the health care system, our goal is to obtain a more accurate diagnosis than the currently available diagnostic methods.

NCT ID: NCT01487681 Recruiting - Cervical Cancer Clinical Trials

Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China

Start date: November 2011
Phase: N/A
Study type: Observational

Human papilloma virus (HPV) infection contributes as a main causative factor to the development of invasive cervical cancer (ICC) and its precursors (cervical intraepithelial neoplasia, CIN). Currently, two prophylactic vaccines are employed for the prevention of genital HPV infection. As the prophylactic efficacy is type-restricted, determining the type-specific HPV distribution and their associations with ICC and its precursors would provide essential information in assessment of HPV vaccination program impact. The baseline information is also important for monitoring possible changes in type-specific HPV distribution after vaccination has been introduced. Prevalence of HPV infection varies considerably across the world, and data were limited from less-developed countries. Knowledge of the detail pattern of HPV type-specific distribution in each region will be essential for public health policy decisions. This will also form the basis for determining which types should be included in future generation HPV vaccines targeted to specific regions. While most studies were focus on ICC and high-grade cervical lesions, the association between HPV types and the progression of CIN1 has rarely been studied. CIN1 is an insensitive histopathological sign of HPV infection, most of which will spontaneously regress to normal with host immune system. However, some genotypes have been described as being more persistent and associated with progression from low-grade lesions to high-grade lesions, even ICC. Geographical data on type-specific prevalence of HPV in CIN1 with appropriately designed prospective studies would be helpful in identifying types preferentially associated with progression to malignancy and accurately predicting the future impact of vaccination in specific regions. Free vaccination supported by the government appears to be unlikely at present in China. Thus, individuals need to pay the cost of vaccines for themselves presently. Yangtze River Delta Area is the most economically developed regions in China, and people here may become the largest vaccinated population at their own expense in China. To the best of the investigators knowledge, no multi-center study on HPV type-specific distribution and their associations with ICC and its precursors is available in Yangtze River Delta Area, China, which highlights the need for timely study in this region before large scale vaccination programs are carried out.

NCT ID: NCT01058460 Recruiting - Cervical Cancer Clinical Trials

HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN

COCY
Start date: June 2010
Phase: N/A
Study type: Interventional

To compare the effects of conventional cytology testing with concommitant HPV-cytology testing for the detection of high grade cervical lesions in primary cervical cancer screening in Hong Kong Hypotheses: 1. There is a significant difference in the number of CIN2+ cases detected between the cytology testing group and the cytology-HPV co-testing group at baseline. 2. Significantly more CIN2+ cases will be detected at the second round of screening among participants with normal cytology result in the control arm than those with normal cytology and negative HPV results in the intervention arm.

NCT ID: NCT00728871 Recruiting - Cervical Cancer Clinical Trials

The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis

Start date: December 2005
Phase: N/A
Study type: Interventional

A. To investigate the relationship between serum titer of anti-HPV16 antibody and clinicopathological factors of cervical cancer patients. B. To investigate that if the serum titer of anti-HPV16 antibody could be a prognostic factor in the cervical cancer patients. C. To investigate the serum titer of anti-HPV16 antibody in HPV16-infected populations with various disease status such as infection only, precancerous lesion, and early and advanced cervical cancer.

NCT ID: NCT00343213 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 1 (CIN 1)

Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.

Start date: June 2006
Phase: N/A
Study type: Interventional

P16INK4a has recently been described as a surrogate marker for HR-HPV associated squamous and glandular intraepithelial lesions of the cervix. The immunohistochemical staining pattern of p16INK4a in high grade intraepithelial neoplasia of the cervix (CIN 2 and 3) is diffuse, whereas in CIN 1 different staining patterns (diffuse, sporadic, focal or negative) can be seen. The aim of our study is to find out whether the p16INK4a staining pattern of CIN 1 is able to predict the outcome of the lesion. The retrospective part of the study includes cervical biopsies of 200 patients with CIN 1 and clinical follow-up for at least 5 years. p16INK4a staining and HPV detection by IHC will be correlated to clinical outcome.The prospective part of the study includes 300 patients with CIN 1 and LSIL on cytology. HPV detection by HCII and p16INK4a immunohistochemistry on liquid based cytology samples as well as p16INK4a staining and HPV detection by ISH on colposcopy guided biopsies will be correlated to clinical follow-up and colposcopy findings. Slides are analysed by 2 pathologists without knowledge of clinical data.